Baseline characteristics (safety population)
| Patient characteristic . | DLBCL safety population (N = 42) . |
|---|---|
| Median age (range) at baseline, y | 65 (22-84) |
| Age category, n (%) | |
| ≥65 y | 22 (52) |
| <65 y | 20 (48) |
| Sex, n (%) | |
| Male | 26 (62) |
| Female | 16 (38) |
| Ann Arbor stage at diagnosis, n (%) | |
| III/IV | 40 (95) |
| IPI risk group at diagnosis, n (%) | |
| Low-intermediate (2) | 11 (26) |
| High-intermediate/high (3-5) | 29 (69) |
| ECOG PS, n (%) | |
| 0-1 | 37 (88) |
| Bone marrow involvement, n (%) | 6 (14) |
| Extranodal involvement, n (%) | 31 (74) |
| Bulky disease (≥7.5 cm), n (%) | 20 (48) |
| Cell-of-origin classification, n (%) (N = 33) | |
| ABC | 11 (33) |
| GCB | 18 (55) |
| Unclassified | 4 (12) |
| Patient characteristic . | DLBCL safety population (N = 42) . |
|---|---|
| Median age (range) at baseline, y | 65 (22-84) |
| Age category, n (%) | |
| ≥65 y | 22 (52) |
| <65 y | 20 (48) |
| Sex, n (%) | |
| Male | 26 (62) |
| Female | 16 (38) |
| Ann Arbor stage at diagnosis, n (%) | |
| III/IV | 40 (95) |
| IPI risk group at diagnosis, n (%) | |
| Low-intermediate (2) | 11 (26) |
| High-intermediate/high (3-5) | 29 (69) |
| ECOG PS, n (%) | |
| 0-1 | 37 (88) |
| Bone marrow involvement, n (%) | 6 (14) |
| Extranodal involvement, n (%) | 31 (74) |
| Bulky disease (≥7.5 cm), n (%) | 20 (48) |
| Cell-of-origin classification, n (%) (N = 33) | |
| ABC | 11 (33) |
| GCB | 18 (55) |
| Unclassified | 4 (12) |
ABC, activated B-cell like; GCB, germinal center B-cell-like.